» Articles » PMID: 35420271

Proposal of an Obesity Classification Based on Weight History: an Official Document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO)

Overview
Specialty Endocrinology
Date 2022 Apr 14
PMID 35420271
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a chronic disease associated with impaired physical and mental health. A widespread view in the treatment of obesity is that the goal is to normalize the individual's body mass index (BMI). However, a modest weight loss (usually above 5%) is already associated with clinical improvement, while weight losses of 10%-15% bring even further benefits, independent from the final BMI. The percentage of weight reduction is accepted as a treatment goal since a greater decrease in weight is frequently difficult to achieve due to metabolic adaptation along with environmental and lifestyle factors. In this document, the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO) propose a new obesity classification based on the maximum weight attained in life (MWAL). In this classification, individuals losing a specific proportion of weight are classified as having "reduced" or "controlled" obesity. This simple classification - which is not intended to replace others but to serve as an adjuvant tool - could help disseminate the concept of clinical benefits derived from modest weight loss, allowing individuals with obesity and their health care professionals to focus on strategies for weight maintenance instead of further weight reduction. In future studies, this proposed classification can also be an important tool to evaluate possible differences in therapeutic outcomes between individuals with similar BMIs but different weight trajectories.

Citing Articles

Sheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery.

Stumpf M, Cercato C, de Melo M, Mancini M Rev Endocr Metab Disord. 2025; .

PMID: 39920515 DOI: 10.1007/s11154-025-09946-9.


Experiences and overall impact reported by people living with obesity: results from a multinational study.

Artime E, Khare S, Zimner-Rapuch S, Redig J, Flannery C, Higgins V SAGE Open Med. 2025; 13:20503121241313082.

PMID: 39871849 PMC: 11770732. DOI: 10.1177/20503121241313082.


Challenges in the care and treatment of patients with extreme obesity.

Stumpf M, Mancini M Arch Endocrinol Metab. 2024; 68:e230335.

PMID: 39420906 PMC: 11326745. DOI: 10.20945/2359-4292-2023-0335.


Ergonomics, Health, and Perceptions about Remote Domestic Workposts: Study in Areas of City of João Pessoa, Paraíba, Brazil.

Silva L, Beserra Melo C, Gomes Lisboa de Souza A, de Oliveira L Int J Environ Res Public Health. 2024; 21(7).

PMID: 39063517 PMC: 11276999. DOI: 10.3390/ijerph21070941.


Combination of Gold Nanoparticles with Carnitine Attenuates Brain Damage in an Obesity Animal Model.

da Silva L, Abel J, Tartari G, da Silva M, de Oliveira M, Dela Vedova L Mol Neurobiol. 2024; 61(9):6366-6382.

PMID: 38296901 DOI: 10.1007/s12035-024-03984-1.


References
1.
Despres J . Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012; 126(10):1301-13. DOI: 10.1161/CIRCULATIONAHA.111.067264. View

2.
Schwartz R, Shuman W, Bradbury V, Cain K, Fellingham G, Beard J . Body fat distribution in healthy young and older men. J Gerontol. 1990; 45(6):M181-5. DOI: 10.1093/geronj/45.6.m181. View

3.
Bertoluci M, Salles J, Silva-Nunes J, Pedrosa H, Moreira R, da Silva Duarte R . Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Diabetol Metab Syndr. 2020; 12:45. PMC: 7245758. DOI: 10.1186/s13098-020-00551-1. View

4.
Harris K, Zopey M, Friedman T . Metabolic effects of smoking cessation. Nat Rev Endocrinol. 2016; 12(11):684. DOI: 10.1038/nrendo.2016.171. View

5.
Muller T, Clemmensen C, Finan B, DiMarchi R, Tschop M . Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. Pharmacol Rev. 2018; 70(4):712-746. DOI: 10.1124/pr.117.014803. View